| First Author | Taylor D | Year | 2023 |
| Journal | Mol Brain | Volume | 16 |
| Issue | 1 | Pages | 6 |
| PubMed ID | 36639708 | Mgi Jnum | J:339503 |
| Mgi Id | MGI:7427963 | Doi | 10.1186/s13041-023-00994-3 |
| Citation | Taylor D, et al. (2023) Tyrosine phosphatase STEP(61) in human dementia and in animal models with amyloid and tau pathology. Mol Brain 16(1):6 |
| abstractText | Synaptic degeneration is a precursor of synaptic and neuronal loss in neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia with tau pathology (FTD-tau), a group of primary tauopathies. A critical role in this degenerative process is assumed by enzymes such as the kinase Fyn and its counterpart, the phosphatase striatal-enriched tyrosine phosphatase 61 (STEP(61)). Whereas the role of Fyn has been widely explored, less is known about STEP(61) that localises to the postsynaptic density (PSD) of glutamatergic neurons. In dementias, synaptic loss is associated with an increased burden of pathological aggregates. Tau pathology is a hallmark of both AD (together with amyloid-beta deposition) and FTD-tau. Here, we examined STEP(61) and its activity in human and animal brain tissue and observed a correlation between STEP(61) and disease progression. In early-stage human AD, an initial increase in the level and activity of STEP(61) was observed, which decreased with the loss of the synaptic marker PSD-95; in FTD-tau, there was a reduction in STEP(61) and PSD-95 which correlated with clinical diagnosis. In APP23 mice with an amyloid-beta pathology, the level and activity of STEP(61) were increased in the synaptic fraction compared to wild-type littermates. Similarly, in the K3 mouse model of FTD-tau, which we assessed at two ages compared to wild-type, expression and activity of STEP(61) were increased with ageing. Together, these findings suggest that STEP contributes differently to the pathogenic process in AD and FTD-tau, and that its activation may be an early response to a degenerative process. |
